Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
1.8K
Cancer Therapies02:49

Cancer Therapies

10.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Delivery of oligonucleotide-based therapeutics: challenges and opportunities.

EMBO molecular medicine·2021
Same author

Next-Generation Sequencing of 487 Esophageal Adenocarcinomas Reveals Independently Prognostic Genomic Driver Alterations and Pathways.

Clinical cancer research : an official journal of the American Association for Cancer Research·2021
Same author

Extracellular vesicle and particle isolation from human and murine cell lines, tissues, and bodily fluids.

STAR protocols·2021
Same author

Cisplatin +/- rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer.

NPJ breast cancer·2021
Same author

Modification of Pathologic T Classification for Non-small Cell Lung Cancer With Visceral Pleural Invasion: Data From 1,055 Cases of Cancers ≤ 3 cm.

Chest·2021
Same author

Targeted therapies for resectable lung adenocarcinoma: ADAURA opens for thoracic oncologic surgeons.

The Journal of thoracic and cardiovascular surgery·2021
Same journal

Pleuropulmonary Infectious Diseases: Impact of the Diseases and the Scarce Literature.

Thoracic surgery clinics·2026
Same journal

TB or Not TB-Septic or Resect? That Is the Question.

Thoracic surgery clinics·2026
Same journal

Surgery for Pulmonary Aspergillosis.

Thoracic surgery clinics·2026
Same journal

Current Treatment for Mediastinitis.

Thoracic surgery clinics·2026
Same journal

Surgical Management of Pulmonary Mucormycosis.

Thoracic surgery clinics·2026
Same journal

Surgical Management of Pulmonary Hydatid Disease.

Thoracic surgery clinics·2026
See all related articles

Related Experiment Video

Updated: Apr 12, 2026

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

15.2K

Do Stage I Patients Need Systemic Therapy?

Stella T Tsui1, Nanruoyi Zhou1, David R Jones1

  • 1Division of Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Thoracic Surgery Clinics
|April 10, 2026
PubMed
Summary
This summary is machine-generated.

Surgery is the main treatment for stage I non-small cell lung cancer (NSCLC). However, some patients recur, highlighting the need for future adjuvant therapies for NSCLC treatment.

Keywords:
ChemotherapyImmunotherapyNon-small cell lung cancerStage ISystemic therapyTargeted therapy

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

11.1K
Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

14.1K

Related Experiment Videos

Last Updated: Apr 12, 2026

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

15.2K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

11.1K
Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

14.1K

Area of Science:

  • Oncology
  • Thoracic Surgery
  • Cancer Research

Background:

  • Stage I non-small cell lung cancer (NSCLC) is primarily treated with surgery.
  • Complete resection of stage I NSCLC has a 10% to 30% recurrence rate.
  • Tumor characteristics like high SUVmax, lymphovascular invasion, visceral pleural invasion, and high IASLC grade predict recurrence risk.

Purpose of the Study:

  • To review the current treatment landscape for stage I NSCLC.
  • To identify factors associated with recurrence after surgical resection.
  • To discuss the potential future role of adjuvant systemic therapies in stage I NSCLC.

Main Methods:

  • Literature review of studies on stage I NSCLC treatment and outcomes.
  • Analysis of prognostic factors for recurrence following surgical resection.
  • Discussion of emerging adjuvant systemic therapies.

Main Results:

  • Surgery remains the standard of care for resected stage I NSCLC.
  • Specific tumor features are associated with a higher risk of disease recurrence.
  • Adjuvant systemic therapy currently has a limited role but is an area of active investigation.

Conclusions:

  • Despite complete resection, a significant proportion of stage I NSCLC patients experience recurrence.
  • Identifying high-risk patients is crucial for considering adjuvant treatment strategies.
  • Future clinical trials investigating targeted therapies and immunotherapies may redefine adjuvant treatment paradigms for stage I NSCLC.